Oncotarget, Passing on Information to the Rest of the World

Oncotarget is a United States Oncology Journal created in 2010. For seven years, Oncotarget has been providing readers across the globe with the latest information dwelling on topics like Neuroscience, Pharmacology, Cardiology, Cell Biology, and Metabolism among many others. With Oncotarget being a free access journal, people interested in matters Oncology have found a reliable platform where they can read validated and well-researched information at no charge.

Since its inception, the journal has also prioritized information centering on cancer and aging. With Oncotarget being a highly sought after editorial, it now features on the SCImago Journal & Country Rank. Nationally, Oncotarget has taken the number 66 spot, a testament to the journal’s reliability. Since 2011, Oncotarget has been experiencing an upward trajectory in the number of views based on its size independent prestige indicator. Over the years, information from Oncotarget journals has become a reference point for many scholars across the globe, with 61% being the average number through which sources from the American Oncology editorial have gotten cited.

From 2011, the number of individuals citing sources from Oncotarget journals has increased by a large margin with the tally averaging 3700 sources annually. At the moment, Oncotarget has gained international acceptance because it has since day one provided valuable and relevant information to researchers and readers across the globe. Some of the notable journals that Oncotarget has created over time include CANcer-specific Evaluation System, Blockade of potassium ion transports enhances hypotonicity-induces cytocidal effects in gastric cancer, and Extracellular sphingomyelinase activity impairs TNF-a-induced endothelial cell death via ADAM17 activation and TNF receptor 1 shedding among many others.

Past and present statistics show that Oncotarget has been gaining fame annually, mainly because of providing a reliable platform for validated information. Through Oncotarget, people have since 2010 been in the know on what goes on in the healthcare world, with a proper emphasis getting placed on cancer and aging. To a large extent, Oncotarget has helped scientists advance their research and cures for particular diseases have gotten discovered in the process. Thus, Oncotarget has ultimately helped revolutionize global health standards.

To know more click here

 

 

Why Eric Lefkofsky Is A Medical Technology Warrior

Cancer is a cruel and puzzling foe that has confounded mankind since its beginning. A disease that causes one’s body to become one’s own worst enemy, cancer seems to have any number of causes, but no apparent cures. Unless one is lucky enough to be declared cancer-free in their battle with it, the best that can be hoped for is to arrest and manage the disease with an array of powerful medications. Unfortunately some of these treatments produce serious and sometimes lethal side effects, and it’s not uncommon to hear that these treatments can be worse than the actual cancer.

Fortunately, technological advances correctly administered now mean that health care providers can create individual biological biographies and administer patient cancer care much more effectively. This is made possible in large part through the efforts of Tempus and its co-founder and CEO Eric Lefkofsky.

Tempus is computer software that allows users to map genomes and body functioning on the molecular level in real time, and use this collected data to make decisions about the best course of action involving individual patients. Tempus also delivers a complete report to physicians after patient scanning that includes current information on clinical trials that patients might qualify for, and detailed information on tumors. Tempus also can be used in conjunction with research involving animal trials to develop new types of cancer therapy.

Eric Lefkofsky is no stranger to being involved in shaking up and improving ways of doing things. In addition to his creation and involvement with Tempus, Eric did similar work in setting up Lightbank, a company that funds disruptive technologies. Disruptive technologies are ones that shake up or transform existing technologies. Next-generation genome tracking, self-driving vehicles, natural resource recovery, and cloud platform technologies are all examples of disruptive ones. And not only are these technologies disruptive, they’re transformative, meaning that they’ll impact on how these industries operate far into the future. This means that cancer patients in decades to come will benefit from the efforts of Tempus and Lefkofsky.

In addition to his Tempus and Lightbank work, Lefkofsky has co-founded Uptake, an analytical data company that provides companies with information to help improve company security and safety. In addition to focusing more recently on Tempus, Lefkofsky has become very involved recently in charitable gift giving.

In 2006, he and his wife Elizabeth founded the Lefkofsky Foundation, and since its creation, have given or pledged millions of dollars around the world, including to the Chicago public school system, and a prominent children’s hospital. He is also either a member of or sits on the board of directors of a number of cultural institutions, including the Steppenwolf Theater Company and the Chicago Institute of Art. But Lefkofsky’s touch and instincts aren’t always perfect. He also served on the committee that failed to bring the Summer Olympics to Chicago in 2016.

More information for Lefkofsky: http://www.bizjournals.com/chicago/news/2016/10/20/groupon-founder-eric-lefkofsky-joins-steppenwolf.html

Tech roundup: Lefkofsky’s Tempus comes out of stealth, AddStructure teams up with Target and more